Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Herceptin Coverage Prior Auth | Op…
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Herceptin (trastuzumab) medical benefit coverage

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit coverage, prior authorization, and administration coding for Herceptin (trastuzumab) for MVP Health Care Medicaid members, primarily for cancer indications; applies to providers submitting medical benefit claims.

    Policy Summary
    PayerMVP Health Care
    PolicyHerceptin (trastuzumab) medical benefit coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization via the MVP Cancer Guidance Program for Herceptin when used for cancer diagnoses; off-label uses also require prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J9355HCPCS code
    96413, 96415Administration CPTs

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medical benefit
    Coverage pathway
    Prior authAuthorization

    Coverage Criteria

    Coverage criteria

    Covered when ALL of the following are met

    On-label cancer indication: Herceptin used for an FDA-approved cancer indication is covered under the member's medical benefit

    Such use is subject to retro-review per policy.

    Authorization for cancer use: Herceptin when used for a cancer diagnosis requires authorization per the MVP Cancer Guidance Program

    Providers must obtain prior authorization as required by the program.

    Off-label use requires prior authorization and must meet MVP's clinical coverage criteria for Experimental or Investigational Procedures and related policies

    Off-label requests are evaluated against MVP's experimental/investigational criteria.

    The policy does not list any additional coverage notes beyond the program-level authorization requirements. Off-label uses of Herceptin are handled through the insurer's experimental/investigational review process and must meet MVP's clinical coverage criteria for Experimental or Investigational Procedures and related policies.

    The document does not specify any conditions that are explicitly deemed not medically necessary. Instead, it states that off-label use requires prior authorization and must meet MVP's clinical coverage criteria for Experimental or Investigational Procedures; such review may render an off-label request non-covered if criteria are not met.

    Coding

    Covered HCPCS CodesHCPCSCovered
    J9355Injection, trastuzumab, excludes biosimilar; 10 mg
    Administration CPT CodesCPTCovered
    96413Chemotherapy administration, intravenous infusion technique; up to 1 hour; single or initial substance/drug
    96415Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure): Use 96415 in conjunction with 96413.

    Provider Actions & Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for trastuzumab (Herceptin) when used to treat cancer diagnoses. Authorization is handled through the MVP Cancer Guidance Program.

    • Herceptin (trastuzumab) used for cancer indications: prior authorization required via the MVP Cancer Guidance Program.
    • Off-label use of Herceptin: prior authorization required and must meet MVP clinical coverage criteria for Experimental or Investigational Procedures, Drugs and Treatments.
    Note

    Providers must request prior authorization through the MVP Cancer Guidance Program for Herceptin when used for cancer diagnoses. For off‑label uses, submit a prior authorization request demonstrating that the request meets MVP's clinical coverage criteria for investigational or experimental therapies.

    Initial Therapy Requirements

    Initial therapy requirements

    Initial coverage rules

    FDA-approved indication: Use for FDA-approved cancer indications is covered under the medical benefit

    Subject to retro-review.

    Prior authorization: Authorization required via MVP Cancer Guidance Program for cancer diagnoses; off-label uses require prior authorization and must meet experimental/investigational criteria

    Site of Care / Administration

    Billing Rule

    Infusion administration coding and site guidance

    Administer Herceptin under the medical benefit using standard chemotherapy infusion administration coding (CPT 96413 for up to 1 hour; 96415 for each additional hour). No additional site‑of‑care restrictions are specified beyond standard medical benefit administration coding.

    • Use 96413 for single/initial infusion up to 1 hour.
    • Use 96415 in conjunction with 96413 for each additional hour.

    Biosimilar Information

    Billing Rule

    HCPCS J9355 specifies trastuzumab and excludes biosimilars

    Bill trastuzumab using HCPCS J9355 (Injection, trastuzumab, excludes biosimilar; 10 mg) as specified; the J9355 descriptor explicitly excludes biosimilars.

    Definitions

    Herceptin (trastuzumab) — definition
    Generic nametrastuzumab
    Brand nameHerceptin
    Drug classHumanized monoclonal antibody (IgG1 kappa) targeting HER2
    Primary indications (documented)HER2-positive breast cancer and gastric cancer
    Mechanism of actionBinds to the HER2 protein (HERZ in document)

    Background

    Herceptin (trastuzumab) is a recombinant humanized IgG1 kappa monoclonal antibody that targets the HER2 protein. It is indicated for certain HER2-positive breast and gastric cancers. The policy clarifies that on‑label cancer indications for Herceptin are covered under the member's medical benefit and are subject to retro‑review, and that use for a cancer diagnosis requires authorization through the MVP Cancer Guidance Program. Off-label uses require prior authorization and must meet the insurer's experimental/investigational criteria.

    Policy Summary
    PayerMVP Health Care
    PolicyHerceptin (trastuzumab) medical benefit coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization via the MVP Cancer Guidance Program for Herceptin when used for cancer diagnoses; off-label uses also require prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions & AuthorizationInitial Therapy RequirementsSite of Care / AdministrationBiosimilar InformationDefinitionsBackground
    Documentation Required

    Coverage and Review Notes

    On‑label (FDA‑approved) use of Herceptin is covered under the member's medical benefit. Coverage is subject to retroactive review. Cancer indications require prior authorization through the MVP Cancer Guidance Program; off‑label indications require prior authorization and must meet MVP's clinical coverage criteria.

    Prior Authorization

    Prior Authorization

    Use of Herceptin for cancer diagnoses is subject to authorization per the MVP Cancer Guidance Program. Off‑label uses are also subject to prior authorization and clinical review under MVP's Experimental or Investigational Procedures policy.